These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6404979)

  • 21. Recurrence rate of hirsutism after 3 different antiandrogen therapies.
    Yücelten D; Erenus M; Gürbüz O; Durmuşoğlu F
    J Am Acad Dermatol; 1999 Jul; 41(1):64-8. PubMed ID: 10411413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
    Spandri P; Gangemi M; Nardelli GB; Meneghetti G; Grandesso R; De Salvia D; Ambrosio GB; Predebon O
    Clin Exp Obstet Gynecol; 1984; 11(1-2):49-54. PubMed ID: 6424970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spironolactone in the treatment of hirsutism.
    Köksal A; Pabuçcu R; Akyürek C
    Arch Gynecol; 1987; 240(2):95-100. PubMed ID: 3105474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose spironolactone in the treatment of female hirsutism.
    Ylöstalo P; Heikkinen J; Kauppila A; Pakarinen A; Järvinen PA
    Int J Fertil; 1987; 32(1):41-5. PubMed ID: 2880814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission.
    Carmina E; Lobo RA
    Fertil Steril; 1998 Jun; 69(6):1075-9. PubMed ID: 9627295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of hirsutism with spironolactone and progestagen combination].
    Pugeat M; Elmidani M; Dechaud H; Garoscio-Cholet M; Lejeune H; Tourniaire J
    Presse Med; 1990 Oct; 19(33):1529-32. PubMed ID: 2146664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of treatment of hirsutism with spironolactone].
    Baranowska B; Stopińska-Głuszak U; Niewiadomska A; Zgliczyński S
    Endokrynol Pol; 1982; 33(1-3):93-8. PubMed ID: 7183446
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
    J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
    Evron S; Shapiro G; Diamant YZ
    Fertil Steril; 1981 Oct; 36(4):468-71. PubMed ID: 6793406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism.
    Müderris II; Bayram F; Sahin Y; Keleştimur F; Tutuş A; Ayata D
    Fertil Steril; 1996 Aug; 66(2):220-2. PubMed ID: 8690105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
    J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance of spironolactone.
    Hughes BR; Cunliffe WJ
    Br J Dermatol; 1988 May; 118(5):687-91. PubMed ID: 2969259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis.
    Bashir R; Asrar MM; Shah IA; Wani IA; Ganie MA
    Curr Pharm Des; 2023; 29(19):1486-1496. PubMed ID: 36999713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spironolactone in the treatment of hirsutism.
    Anttila L; Ruutiainen K; Erkkola R
    Ann Chir Gynaecol Suppl; 1987; 202():32-4. PubMed ID: 3310825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of spironolactone on sex hormones in man.
    Stripp B; Taylor AA; Bartter FC; Gillette JR; Loriaux DL; Easley R; Menard RH
    J Clin Endocrinol Metab; 1975 Oct; 41(4):777-81. PubMed ID: 1176584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.
    Wong IL; Morris RS; Chang L; Spahn MA; Stanczyk FZ; Lobo RA
    J Clin Endocrinol Metab; 1995 Jan; 80(1):233-8. PubMed ID: 7829618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.